Background Image
Table of Contents Table of Contents
Previous Page  593 / 1498 Next Page
Information
Show Menu
Previous Page 593 / 1498 Next Page
Page Background

StiL R-Benda vs R-CHOP

Rummel MJ et al : Lancet Feb 20, 2013

~ PFS; Primary end-point NOT censored for other therapies ~

•B-R more favorable acute tolerability profile. Severe neutropenia was markedly decreased with B-R (29% vs. 69% with

RCHOP), less parasthesias, stomatitis and infections